By Colin Kellaher
Shares of Soleno Therapeutics took flight in premarket trading Thursday after the biopharmaceutical company won U.S. Food and Drug Administration approval of its treatment for a genetic disorder that can lead to obesity, diabetes and cardiovascular disease.
Soleno on Wednesday said the FDA approved its Vykat XR extended-release tablets for the treatment of hyperphagia, a chronic and life-threatening feeling of intense, persistent hunger, in people ages 4 and older with Prader-Willi syndrome.
The Redwood City, Calif., company said the green light makes Vykat XR the first FDA-approved therapy to address hyperphagia in individuals with Prader-Willi syndrome, a rare genetic neurodevelopmental disorder, adding that it expects the drug to be available in the U.S. beginning next month.
Soleno shares, which closed Wednesday at $48.97, were recently up 38% at $67.50 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 27, 2025 06:07 ET (10:07 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。